Inflammation is a complex biological response to harmful stimuli such as pathogens or tissue injury in which several cells and chemical mediators take part to neutralize the injurious element and initiate the healing process. In the absence of inflammation, wound and infections would never heal. However an excessive or prolonged inflammatory response would also be detrimental, as it would cause excessive tissue damage and loss of function. Inflammation is then a protective response characterized by a tightly regulated balance between pro-inflammatory and pro-resolving mechanisms. 1, 2 Neutrophil apoptosis is a crucial event for an effective resolution of inflammation, as it determines the number of activated neutrophils present in the inflammatory sites. 3, 4 The processes of neutrophil apoptosis, and their subsequent phagocytic clearance by macrophages (efferocytosis), have been proposed as novel therapeutic targets to treat inflammatory diseases. 5, 6 Therefore, new concepts regarding the management of inflammation are emerging from these novel approaches: not only is necessary modulation (yet not the abrogation) of pro-inflammatory events, but promotion and enhancement of endogenous pro-resolving pathways, is required to achieve control of the inflammatory response with rapid restoration of tissue homeostasis. 7, 8 A novel approach to drug discovery, the Connectivity Map (CMap), proposed by Lamb et al. 9, 10 and recently validated by Sirota et al., 11 demonstrates how integrating genome-wide gene expression data of drugs and diseases can be used for compound repositioning (i.e., application of known drugs to new indications), or for discovery of new drugs, reducing costs and years required for their development. The CMap is a publicly available collection of genome-wide gene expression signatures of human cells treated with a number of bioactive small molecules, most of which are FDA-approved drugs. The most recent version contains 7056 gene expression profiles from 1309 bioactive compounds, representing 6100 individual treatments in five different human cell lines. This database can be queried with any gene-expression profile of interest (e.g., the expression profile of a compound, or a disease) and the results yield a list of the CMap drugs ranked, according to the similarity with the signature of interest. Hence, drugs with new treatments for specific diseases, 12-14 while drugs with positive score (similar profiles) could be useful for identification of novel actions of existing drugs 15 or to unravel drug mechanisms of action. [16] [17] [18] Using the gene expression profile produced by the antiinflammatory pro-resolving molecule annexin A1 (AnxA1), 19 we found very strong positive connections with several members of the histone deacetylase inhibitors (HDACIs) class of drugs. HDACIs are being actively investigated for the treatment of cancer owing to their pro-apoptotic effect, 20, 21 although a substantial body of evidence indicates that this chemically-unrelated family of molecules affords potent anti-inflammatory properties 22, 23 with potential therapeutic in pathologies including rheumatoid arthritis, 24, 25 inflammatory bowel disease 26 and heart disease. 27, 28 The mechanisms underlying these anti-inflammatory properties of HDACIs are largely not understood. In the present work, we performed a re-interpretation of genome-wide expression data using the CMap to reveal a mechanistic association between HDACIs and the pro-resolving molecule AnxA1.
Results
Query of the CMap database identifies a novel link between AnxA1 and HDACIs. The gene expression signature of AnxA1 on HEK293 cells transfected with the receptor FPR2/ALX, consisting of 118 genes (described in 29 ) , was used to query the most recent version of the CMap database. Not too surprising in view of the anti-inflammatory nature of AnxA1, strong connections (positive score) were found with several NSAIDs and glucocorticoids, validating the use of the 118 genes signature to generate new predictions (score, cell line): paracetamol (0.933 in HL60 cells), aceclofenac (0.672, PC3; 0.509, MCF7), acetylsalicylic acid (0.307, MCF7), ketoprofen (0.733, HL60), diflunisal (0.629, HL60), naproxen (0.481, HL60), beclomethasone (0.995, HL60) or dexamethasone (0.742, HL60; 0.378, MCF7). More interestingly, consistent positive connections were found with several drugs of the HDACI family (Table 1) . Several distinct hypotheses could be derived from these results, including the possibility that AnxA1 might have HDACI activity. However, as previous studies in the cancer field suggest that HDACIs engage, in a yet unclear manner, endogenous AnxA1, [30] [31] [32] we hypothesized that also the antiinflammatory effects of HDACIs might be reliant, at least in part, on this pro-resolving mediator.
HDACIs induce the release of AnxA1 by peritoneal macrophages and bone marrow neutrophils. Neutrophils and macrophages contain high levels of AnxA1, which is normally stored inside their cytosol and it is released upon activation during ongoing inflammation. Drugs like glucocorticoids exert part of their non-genomic actions by inducing release of AnxA1. Thus, we tested if HDACIs could mobilize AnxA1 in murine peritoneal macrophages and bone marrow isolated neutrophils.
Western blotting analyses ( Figure 1a) showed a concentration-dependent accumulation of AnxA1 in supernatants of macrophages treated for 30 min with three distinct HDACIs, namely valproic acid (VPA), sodium butyrate (SB) or trichostatin A (TSA), before LPS stimulation for 4 h. Timecourse studies revealed major differences at earlier time points, with maximal release of AnxA1 at 0.5-1 h after treatments (Figure 1b) . The involvement of protein kinase C and protein phosphatase 2A, indicated to have a mechanistic role in AnxA1 release, was investigated using protein kinase C (PKC [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , 5 mM) and protein phosphatase 2A (okadaic acid, 10 nM) inhibitors. However, as shown in Supplementary Figure S1 , we did not observe a common pattern of effect of these inhibitors on the HDACIs investigated.
In primary neutrophils, application of HDACIs did not augment AnxA1 release above levels observed in unstimulated cells (Figure 1c) . However, when AnxA1 expression was analyzed at shorter incubation time, data were different. In fact, cell incubation with compounds for 10-min incubation with HDACIs induced AnxA1 release and, consequently, reduced cytosolic levels both in macrophages ( Figure 1d ) and neutrophils ( Figure 1e ). Collectively, these data indicate that HDACIs induce the release of pre-stored AnxA1.
The anti-cytokine effect of HDACIs on macrophages is independent of AnxA1. The increase of AnxA1 released in supernatants was mirrored by a dose-response decrease of IL-6 and TNF-a release by all three HDACIs (Supplementary AnxA1 and HDACIs in inflammation T Montero-Melendez et al Figure S2 ), which was not associated to apoptosis induction at the time point studied, as analyzed by AnxAV/PI staining. This indicated a genuine anti-inflammatory effect for the three compounds not consequent to cell damage or death. From this set of experiments, concentrations of 1.25-5 mM of VPA and SB, as well as 31.25-125 nM of TSA, were selected for subsequent analyses, as they afforded maximal AnxA1 release and cytokine reduction, without promoting apoptosis.
To assess whether the anti-cytokine effect was mediated by mobilization of endogenous AnxA1, we used peritoneal macrophages obtained from wild type (WT) and AnxA1 À / À mice. However, the degree of inhibition of IL-6 and TNF-a attained by the HDACIs was identical in both macrophage genotypes (Figures 2a-b) . The behavior of both cell types regarding gene expression was also very similar ( Figure 2c HDACIs promote apoptosis and phagocytosis via endogenous AnxA1. One of the most important events required for the effective resolution of an acute inflammatory reaction is the induction of immune cell apoptosis with prompt removal of apoptotic cells.
Of interest, here is the notion that HDACIs can induce apoptosis on neutrophils, 33 and this effect contributes to their profile as anti-inflammatory compounds. To assess if AnxA1 mediated these actions, we used bone marrow cells from WT and AnxA1 À / À mice, and incubated them with VPA, SB or TSA for 6 h. Apoptosis was studied specifically in the Ly6G þ population (Figure 3a ). HDACIs were able to induce apoptosis to a greater extent in WT compared with AnxA1 À / À neutrophils as shown in Figure 3b , providing strong support to the positive role played by endogenous AnxA1 in HDACIinduced apoptosis of mouse neutrophils.
On a similar vein, to study if HDACIs influence the phagocytic properties of macrophages, WT and AnxA1 À / À cells were incubated with fluorescent zymosan at a 1 : 10 ratio (macrophage to zymosan) after 30-min pre-treatment with . Supernatants, membrane-bound and cytosolic AnxA1 expression was quantified, with the latter being normalized to b-actin levels. AnxA1 bands were quantified using ImageJ64 software. In all cases data are mean ± S.E.M. of at least three independent experiments, with blots displaying representative ones
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HDACIs. Efferocytosis was studied in a similar way using CFSE-labeled apoptotic neutrophils, at a 1 : 2 ratio (macrophage to neutrophil). As shown in Figure 4 , the enhancing effects of HDACIs on phagocytosis of zymosan (Figure 4a ), as well as efferocytosis (Figure 4b ) evident in WT cells, were abrogated in AnxA1 À / À macrophages. The latter protocol was used to explore the involvement of receptors that could mediate the effect of endogenous AnxA1 in these experimental settings. Thus, VPA and TSA were added to the cells in the presence of WRW 4 peptide (FPR2-selective antagonist) or cyclosporin H (FPR1-selective antagonist). These data indicated, again, differences in the mechanisms of action of the distinct HDACIs. While the effect of VPA was prevented by both antagonists, TSA pro-efferocytic effect was only affected by the FPR1 antagonist cyclosporin H (Figure 4c) .
Collectively, these data describe novel non-genomic actions of HDACIs, promotion of apoptotic and phagocytosis, centred on endogenous AnxA1. As these two processes are fundamental in the resolution of inflammation, we then tested if HDACIs could accelerate the resolution of ongoing inflammatory reaction.
AnxA1 mediate the pro-resolution actions of HDACIs during ongoing inflammation. Zymosan-induced peritonitis was selected as a model amply applied to study the resolution processes. A first experiment was conducted with VPA in WT and AnxA1 À / À mice, which were pre-treated for 30 min with vehicle/drug before zymosan (1 mg/mouse) injection. Supplementary Figure S3 shows a modest but significant reduction on neutrophil infiltration, only in WT mice, as assessed 4 h after post-zymosan. In view of the in vitro pro-resolving mechanisms activated by HDACIs, we hypothesized higher pharmacological efficacy when given at the peak of neutrophilic inflammation.
Drugs were then given 12 h after zymosan injection, and mice monitored for further 14 h. Vehicle-treated WT and AnxA1 À / À mice showed similar inflammatory cell profiles (Figure 5a) , with slightly less neutrophils in AnxA1 À / À mice, although among normal values expected for this model. However, although the number of apoptotic macrophages was identical, there was an important increase in the number of apoptotic neutrophils in knockout mice compared with WT (Figure 5b ), suggesting perhaps a defect in apoptotic neutrophil clearance in vivo.
The three HDACIs were able to significantly reduce the total cells, neutrophils and monocytes/macrophages numbers in WT mice but not in AnxA1 À / À (Figure 5c ), indicating that, also in vivo, AnxA1 is crucial for the anti-inflammatory actions of HDACIs. VPA and, even more, SB provided consistent modulation of these parameters, whereas TSA did not produce a significant effect on any of them (Figure 5c ). It is plausible that over a 12-h period, pharmacokinetic characteristics associated to each compound could underlie these differences. More importantly, further information was acquired by analysis of cell apoptosis: both VPA and SB-that inhibited immune cell values in WT mice-augmented the extent of cell apoptosis selectively for neutrophils and not macrophages (Figure 5d ). Such a pronounced effect determined during the dynamics of an ongoing resolving inflammatory reaction was absent in AnxA1 À / À mice.
Discussion
Gene expression data has traditionally been used to identify a number of genes or pathways associated with a disease or 
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AnxA1 and HDACIs in inflammation T Montero-Melendez et al drug application. Novel approaches include the use of gene expression data for class discovery, 34 to generate prognosis predictors in cancer 35, 36 and, more recently, to find 'connections' between drug-disease or drug-drug pairs using the CMap. 9 Drug repositioning strategies, which aim to identify if drugs used for one disease could be applied to another, can benefit from this new approach. 11, 12, 14 The mechanisms of action of many drugs already on the market are not always completely understood. The CMap strategy can be of great help to this purpose, as gene expression signature of a particular drug can be used to query the database and explore connections with existing drugs. As an example, using this strategy, Hieronymus et al. 16 found that the natural compounds celastrol and gedunin act as HSP90 inhibitors .
AnxA1 is a 37-kDa glucocorticoid-regulated protein with multiple actions on the events that regulate the immune responses. 19 To unravel new connections between AnxA1 and other molecules, we queried the CMap with the previously reported gene expression signature produced by AnxA1 in FPR2-transfected HEK293 cells. 29 Interestingly, we found very robust positive connections with multiple HDACIs, which act by inhibiting HDAC enzyme activity altering the balance in favor of acetylated histones, leading to an increase in transcription of specific genes. Although HDACIs present an important potential as anti-inflammatory drugs, little is known about the actual mechanisms of action they activate to exert these bioactions. The strong connection found between AnxA1 and HDACIs (see Table 1 ), together with previous reports showing an association between the pro-apoptotic effect of HDACIs and this protein in cancer cells, [30] [31] [32] made us hypothesize that AnxA1 might be mediating at least some of the aspects of the complex anti-inflammatory machinery activated by HDACIs. Conversely, HDACIs might be not solely anti-inflammatory drugs, but by engaging the AnxA1 pathway they can exert pro-resolving effects.
The three pan-inhibitors of histone de-acetylases promoted a time and concentration-dependent increase of AnxA1 release, mirrored by a reduction in TNF-a and IL-6 on LPSstimulated cells. However, cytokine reduction by HDACIs is consequent to direct gene expression modulation 37 hence is AnxA1 independent, as demonstrated with WT and AnxA1 À / À cells. HDACIs also induce the release of AnxA1 by neutrophils, and this response was faster, peaking at 10 min. It is possible that release of functional AnxA1 from macrophages and neutrophils promoted by HDACIs would follow different pathways, as macrophages are more 'longacting' cells, in contrast to neutrophils, which generally can react very rapidly by mobilizing their granules. Endogenous AnxA1 is emerging as an important effector of resolution. It induces neutrophil apoptosis, 38 can promote phagocytosis 39 and efferocytosis, 40 and it acts as a fail-safe mechanism when released from secondary necrotic cells. 41 It was therefore natural to assess the ability of HDACIs in promoting phagocytosis.
In macrophages, VPA, SB and TSA mobilized AnxA1 and increased the engulfment of zymosan particles or apoptotic neutrophils. Removal of apoptotic cells is a pivotal step toward resolution, preventing secondary necrosis, which would further ignite the inflammatory response 42 ; therefore, these results, coupled to the ability of HDACIs to promote neutrophil apoptosis in WT but not AnxA1 À / À cells, indicate that processes central to inflammatory resolution 8, 43 can be promoted by HDACIs through mobilization of endogenous AnxA1.
AnxA1 can engage receptors of the FPR family expressed by macrophages and neutrophils. In our settings, use of selective antagonists 44 indicated a role for FPR2 (also referred to as FPR2/ALX) in the actions of VPA, whereas both VPA and TSA can operate through FPR1. Although fulllength AnxA1 does not bind to human FPR1, N-terminalderived peptides do (e.g., peptide Ac2-26 45 ); we postulate that cell incubation with both HDACIs might lead to the activation of a proteolytic activity that, downstream, would cause generation of FPR1 agonists from the externalized AnxA1. While this hypothesis needs to be tested further, the data generated with these antagonists are coherent with a model whereby-once externalized-endogenous AnxA1 would act in a juxtacrine/paracrine fashion on FPRs to augment phagocytosis. A recent study, conducted with macrophages, confirmed the central role of FPR2 in this process when elicited by either lipoxin A 4 or AnxA1-derived peptides. 46 These in vitro data, and the implications they induce, were translated in vivo by testing whether resolution of an ongoing inflammatory reaction could be accelerated upon HDACIs application. The zymosan-induced peritonitis model was deemed ideal, as used to detail the dynamics of resolution of acute inflammation 47 and characterized by marked AnxA1 gene expression in extravasated cells. 48 The model responds to treatments that modulate cell apoptosis and/or phagocytosis as shown, for example, upon application of resolvin E1 49 ; the same processes are activated by phosphodiesterase inhibitors in active resolving inflammation induced by LPS. 50 In these settings, SB, and to a lesser extent VPA, displayed significant inhibitory properties, whereas TSA produced milder effects. As HDACIs comprise very different chemical entities, it is not surprising that they may only share in part other biological properties. The variable in vivo efficacy could also be linked to the distinct pharmacokinetics characteristics of each molecule administered during ongoing inflammation.
Comparison of the extent of cell infiltration post-zymosan injection in WT and AnxA1 À / À did not reveal major differences, except for the number of apoptotic neutrophils quantified in the peritoneum at the 26-h time point, which is probably secondary to a defect in efferocytosis, as discussed above. Therapeutic delivery of SB reduced the total number of cells, as well as neutrophils and monocytes/macrophages numbers in WT mice, but not in AnxA1 À / À : this clear cut result supports the mechanistic link between this effector of endogenous resolution and HDACIs.
Analysis of neutrophil apoptosis indicates that the actions of HDACIs might be related to the induction of this process, through AnxA1 release and engagement of its receptors, which would plausibly couple with enhanced efferocytosis. A recent study conducted with a model of experimental pleurisy revealed fundamental actions of endogenous and intact AnxA1 in controlling acute inflammation by promoting neutrophil apoptosis. 51 Furthermore, Pupjalis et al. 52 reported that AnxA1 released from apoptotic neutrophils has an antiinflammatory role by reducing pro-inflammatory cytokines release from monocytes via FPRs. Our present findings support the hypothesis that the efficacy of HDACIs in models of acute and chronic inflammation, especially if characterized by a neutrophilic component, could be consequent to potentiation of AnxA1-mediated pro-resolution properties. 53 In conclusion, we report how integrative genome-wide computational approaches can be useful for the discovery of drug mechanisms of action. Our results add new knowledge to the complex anti-inflammatory mechanisms of action of HDACIs, showing that the mediator AnxA1 has non-redundant function especially for their pro-resolving effects, some of which described here for the first time (e.g., pro-phagocytic properties).
Materials and Methods
In silico prediction and hypothesis generation. We previously reported the gene expression signature of AnxA1 on FPR2-transfected HEK293 cells (Renshaw D et al, 29 GEO ID: GSE14807). Briefly, cells were treated with 0.5 mM AnxA1 for 4 h and gene expression analyzed using the whole-genome microarrays Human Genome U133 Plus 2.0 Arrays (Affymetrix, Inc. Santa Clara, CA, USA). After normalization, data analysis and filtering, we identified 118 differentially expressed probes. This AnxA1 gene expression signature was compared with the 47000 gene expression profiles obtained from 1309 small molecules studied in different cultured human cell lines (mainly MCF-7, PC3 and HL60) contained in the new version (build 02) of the Connectivity Map (CMap, http://www.broadinstitute.org/cmap/). The similarity between the gene expression profile of interest and those contained in the CMap database is determined by the connectivity score, ranging from À 1 to þ 1. Considering the hypothesis that if a drug has a gene expression signature that is similar to another drug could potentially be used to identify novel mechanisms of action, we made our predictions on the basis of positive connectivity score values and considering specificity (an estimation of the connectivity between a compound in the CMap database and gene expression signatures extracted from The Molecular Signatures database (MSigDB)) and P-values.
Animals. Male age-matched 7-8-week old mice were maintained on the standard chow pellet diet and had free access to water, with a 12-h light-dark cycle. AnxA1-deficient (AnxA1 À / À , on a C57BL/6J background) 54 and wild-type C57BL/6J mice were purchased from Charles River (Edinburgh, UK). All animal studies were approved by and performed under the guidelines of the Ethical Committee for the Use of Animals, Barts and The London School of Medicine and Home Office regulations (Scientific Procedures Act, 1986).
Compounds. The HDAC inhibitors valproic acid (VPA), trichostatin A (TSA) and sodium butyrate (SB) were purchased from Sigma-Aldrich, Poole, UK. Cyclosporin H (a selective FPR1 antagonist) was purchased from Enzo Life Sciences, Exeter, UK. The selective FPR2 antagonist WRW 4 was purchased from Calbiochem, Nottingham, UK. The PKC inhibitor (PKC [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] ) and the protein phosphatase 2 inhibitor (okadaic acid) were purchased from Tocris Bioscience, Bristol, UK.
Zymosan-induced peritonitis. Peritonitis was induced by injection of 1 mg zymosan A (Sigma-Aldrich) i.p. in 0.5 ml PBS. After 12 h, mice (n ¼ 5 per group) were treated with compound/vehicle and sacrificed 14 h later (time point 26-h postzymosan) by CO 2 exposure. Peritoneal cavities were washed with 4 ml of ice-cold AnxA1 and HDACIs in inflammation T Montero-Melendez et al PBS containing 3 mM EDTA and 25 U/ml heparin. Cells were counted on a Neubauer haemocytometer using Turk's solution and analyzed by flow cytometry (BD FACSCalibur, Oxford, UK), following staining along canonical protocols with the specific antibodies: FITC-Ly6G/Gr1, APC-F4/80, isotype controls and blocking antibody anti-mouse CD16/32, all from eBioscience (San Diego, CA, USA) and used according to the manufacturer's instructions.
Primary peritoneal macrophages. Mice were injected i.p. with 1 ml of 2% biogel (Bio-Rad, Hemel Hempstead, UK); 4 days later, the peritoneal cells were collected by lavage using 4 ml of 3 mM EDTA in PBS and plated in 24-well plates at a density of 0.5 Â 10 6 cells/well, in RPMI-1640-containing 10% FCS and 50 mg/ml gentamycin. After 2 h of incubation, non-adherent cells were removed leaving adherent macrophages (490% enriched population). Compounds or vehicle were added in 1%FCS medium for 30 min before stimulation with 75 ng/ml LPS (Sigma-Aldrich). Supernatants (for western blot and ELISA determinations) and cell pellets (for RNA extraction) were collected after 4 h and kept frozen at À 80 1C until used.
Bone-marrow neutrophil isolation. WT and AnxA1 À / À mice were killed, and the femurs were excised. The epiphyses were removed, and bone marrow was flushed from the bone using HBSS buffer using a syringe equipped with a 23-gauge needle. Cell suspensions were then filtered using a 70 mm mesh nylon strainer. Neutrophils were separated using the EasySep negative selection mouse neutrophil enrichment kit (STEMCELL Technologies, Grenoble, France). Neutrophils were then plated in 96-well plates in RPMI-1640-containing 10% FBS and treated for 6 h with compounds or vehicle.
Western blot analysis. Cell supernatants (400 ml) were collected after corresponding treatments. To collect the membrane-bound fraction, cells were washed with Ca 2 þ -containing PBS and then incubated for 2 min with 200 ml of 1 mM EDTA in Ca 2 þ -free PBS. The recovered supernatants contained the membrane-bound proteins. Finally, cells were lysed with 200 ml of RIPA buffer (Thermo Scientific, Leicestershire, UK) containing protease inhibitors cocktail (Calbiochem).
Samples were subjected to standard SDS-polyacrylamide gel electrophoresis, and transferred onto polyvinylidene difluoride membranes (Millipore, Watford, UK). These were incubated with rabbit anti-AnxA1 (1 : 5000; Invitrogen, Paisley, UK) for 2 h and horseradish peroxidase-conjugated anti-rabbit IgG for 1.5 h (1 : 2000; Dako, Cambridge, UK). Cell lysates membranes were re-blotted with anti-b-actin antibody (1 : 10 000, SIGMA, Dorset, UK). Proteins were detected using an enhanced chemiluminescence detection kit and visualized on Hyperfilm (GE Healthcare).
Neutrophil isolation from human blood. Experiments using healthy volunteers were approved by the local research ethics committee (P/00/029 East London and The City Local Research Ethics Committee 1). Informed written consent was provided, according to the Declaration of Helsinki. Blood was collected into 3.2% sodium citrate and diluted 1 : 1 in RPMI-1640 before separation through a double-density gradient using Histopaque 10771 and 11191 (SigmaAldrich). After polymorphonuclear cells and PBMCs isolation and washing, contaminating erythrocytes were removed by hypotonic lysis. polymorphonuclear cells were re-suspended at a concentration of 4 Â 10 6 cells/ml in 10% FCScontaining medium and incubated overnight at 37 o C, 5%CO 2 to let neutrophils undergo spontaneous apoptosis.
ELISA determinations and enzyme immunoassay. Levels of IL-1b, TNF-a and IL-6 were quantified in the supernatants from cultured macrophages using ELISA Ready-SET-Go (eBioscience, Hatfield, UK), according to the manufacturer's instructions.
RNA extraction, cDNA synthesis and real-time PCR. Total RNA was extracted using the RNeasy Mini Kit and genomic DNA removed by oncolumn digestion with RNase-Free DNase Set, following the manufacturer's instructions (QIAGEN, Crawley, UK). cDNA was synthetized using 1 mg of pooled RNA from three or more samples with the SuperScript III Reverse Transcriptase (Invitrogen). Real-time PCR was performed in duplicates, with 200 ng of cDNA per well, 1ml primers and Power SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK), using the ABI Prism 7900HT Sequence Detection System. Quantitect primers (QIAGEN) used are the following: Gapdh (QT01658692), Il6 (QT00098875), Tnf (QT00104006), Fpr1 (QT01165899), Fpr2 (QT00171514) and AnxA1 (QT00145915). Dissociation step was always included to confirm the absence of unspecific products. Fold change was calculated as 2 À DDCt using Gapdh as reference gene.
Assays of phagocytosis and efferocytosis. Primary peritoneal macrophages were cultured in 1% FCS medium-containing compounds/vehicle for 30 min before the addition of FITC-zymosan A (Invitrogen) at 1 : 10 ratio (macrophage to zymosan) for 15 min, or CFSE-labeled apoptotic neutrophils (1 : 2, macrophage to neutrophil) for 1 h. Cells were washed three times with ice-cold PBS and fluorescence analyzed using a NOVOstar reader (BMG Labtech, Ortenberg, Germany).
Assessment of apoptosis. Cells were stained with APC-Ly6G/Gr1 (1 : 100, eBioscience) to detect neutrophils population and FITC-AnxAV and propidium iodide (PI) using the apoptosis detection kit from BD Pharmingen (Oxford, UK), following the manufacturer's instructions and analyzed by flow cytometry (BD FACSCalibur).
Statistics. Experiments were done at least in triplicates and repeated 3-5 times. Experiments involving human donors were repeated at least two times. The Student's t test or one-way ANOVA, followed by Dunnett's multiple-comparison tests were applied as appropriate considering P-values o0.05 significance.
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